These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6885209)

  • 1. Contemporaneous administration of digitalis and dilazep to subjects with heart failure of ischemic etiology.
    Pasotti C; Gandolfi P; Ottolenghi L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):370-3. PubMed ID: 6885209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiodynamic changes induced with dilazep in chronic coronary insufficiency].
    Fogari R
    G Ital Cardiol; 1980; 10(12):1675-8. PubMed ID: 7250592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled clinical trial of propranolol alone and in combination with dilazep in patients with angina pectoris.
    Biswas NR; Pandhi P; Wahi PL; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1990 Jun; 28(6):241-4. PubMed ID: 2198233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance of anti-ischemic and hemodynamic effects of captopril in stable coronary artery disease.
    Winkelmann BR; Matheis G; Kleist P; Pötter S; Wohltmann D; Kaltenbach M
    Coron Artery Dis; 1994 Oct; 5(10):829-44. PubMed ID: 7866603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of coronary heart disease using Cormelian-Digotab: influence of the duration of therapy. 2. Field study by 107 physicians].
    Pollter J; Schnitker J
    Med Welt; 1976 Oct; 27(43):2074-9. PubMed ID: 792623
    [No Abstract]   [Full Text] [Related]  

  • 6. [Noninvasive quantitative evaluation of cardiac reverse--effects of dilazep (adenosine like agent)].
    Morishita T; Arai C; Abe N; Takeuchi K; Hasegawa M; Takayama Y; Emori I; Yoshinori K
    Kokyu To Junkan; 1988 Jun; 36(6):675-9. PubMed ID: 3217607
    [No Abstract]   [Full Text] [Related]  

  • 7. Problems of an optimum digitalis therapy.
    Haustein KO; Hentschel H; Kaiser B
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(8):352-6. PubMed ID: 7409938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Administration of cormelian in coronary insufficiency. Results of a double blind study].
    Bremer P; Dölle P; Pollter J; Schnitker J; Schumacher KM
    Med Monatsschr; 1975 Dec; 29(12):577-80. PubMed ID: 1107787
    [No Abstract]   [Full Text] [Related]  

  • 9. [Statistical evaluation of a cooperative study toward investigation of the effectiveness of the coronary stimulant dilazep in ischemic heart disease. 1. Epidemiological situation of coronary heart disease].
    Schneider VB; Feldmann U; von Brachel H; Schnitker J; Gelbhaar H
    Arzneimittelforschung; 1974 Nov; 24(11A Suppl):1853-64. PubMed ID: 4480270
    [No Abstract]   [Full Text] [Related]  

  • 10. [Behavior of heart rate and systolic arterial pressure during isometric exercise after administration of salbutamol, dilazep, indomethacin and a placebo].
    Arosio A; Sergi M; Grisetti GC; Mandelli V; Bosisio E
    Minerva Cardioangiol; 1982 Jun; 30(6):309-12. PubMed ID: 7133419
    [No Abstract]   [Full Text] [Related]  

  • 11. [Polygraphic and electrocardiographic study of a new coronary therapeutic agent: dilazep].
    Parenti B; Selvaggi R
    Clin Ter; 1980 Jan; 92(2):155-63. PubMed ID: 7389275
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inotropic effect of digitalis. II. Ischemic heart disease].
    Pidrman V; Hamet A; Mihulová L
    Cas Lek Cesk; 1968; 107(41):1232-6. PubMed ID: 5680309
    [No Abstract]   [Full Text] [Related]  

  • 13. [Statistical evaluation of a cooperative study toward investigation of the effectiveness of the coronary stimulant dilazep in ischemic heart disease. 3. Influence of the duration of therapy and co-medication on the therapeutic result. Secondary effects and discontinuation of therapy].
    Schneider VB; Feldmann U; von Brachel H; Schnitker J; Gelbhaar H
    Arzneimittelforschung; 1974 Nov; 24(11A Suppl):1873-9. PubMed ID: 4155950
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of digitalis in the treatment of heart failure: data from the Italian Network on Congestive Heart Failure (IN-CHF).
    Camerini A; Griffo R; Fabbri G; Aspromonte N; Ingrillì F; Lucci D; Naccarella F; Maggioni AP;
    Ital Heart J; 2004 Jul; 5(7):523-9. PubMed ID: 15487270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the cardiac and peripheral vascular effects of strophantin K and lanatoside C in coronary heart disease.
    Matos L; Békés M; Polák G; Rausch J; Török E
    Eur J Clin Pharmacol; 1975 Oct; 9(1):27-37. PubMed ID: 1233250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of dilazep on circulating platelet aggregation in diabetics].
    Carleo R; Buda GR; Cerciello A; Dell'Aversano R; Monaco GP; Trovato C; Vigilante M
    Boll Soc Ital Biol Sper; 1983 Dec; 59(12):1832-7. PubMed ID: 6671042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term effect of dilazep therapy in patients with chronic glomerulonephritis and nephrotic syndrome].
    Takasaki H; Shibata M; Ito S; Kida H; Morozumi K; Iwata J
    Nihon Jinzo Gakkai Shi; 1987 Jan; 29(1):87-96. PubMed ID: 3586400
    [No Abstract]   [Full Text] [Related]  

  • 18. [Myocardial protection by dilazep in myocardial ischemia and reperfusion].
    Shida H; Kobayashi M; Chiba S
    Arzneimittelforschung; 1981; 31(11):1902-6. PubMed ID: 7198472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dilazep].
    Pirani R; Gruppillo P
    G Ital Cardiol; 1980; 10(10):1419-25. PubMed ID: 7016654
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
    Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
    Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.